Tasquinimod - Active Biotech
Alternative Names: ABR-215050; TASQLatest Information Update: 19 Jun 2025
At a glance
- Originator Active Biotech
- Developer Active Biotech; Ipsen; University of Pennsylvania
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Phase II Myelofibrosis
- Phase I/II Multiple myeloma
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
- Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer
Most Recent Events
- 09 Jun 2025 Updated efficacy and adverse event data from a phase I/II trial in Multiple Myeloma released by Active Biotech
- 23 May 2025 Updated adverse events and efficacy data from a phase I/II trial in Multiple myeloma released by Active Biotech
- 20 Feb 2025 Phase-I/II clinical trials in Myelofibrosis (Second-line therapy or greater) in Netherlands (PO) (NCT06605586)